Cocrystal Pharma names James Sapirstein CEO, replacing co-CEOs Lee and Martin

Cocrystal Pharma Inc

Cocrystal Pharma Inc

COCP

0.00
  • Cocrystal Pharma named James Sapirstein chief executive officer, effective immediately; it also plans to add him to the board.
  • Sapirstein previously led Contravir Pharmaceuticals as CEO; he also served as founding CEO of Tobira Therapeutics.
  • Sam Lee stepped down as co-CEO, staying on as president, transitioning to chief scientific officer.
  • Jim Martin exited the co-CEO role, remaining chief financial officer.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cocrystal Pharma Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606030700PRIMZONEFULLFEED9730928) on June 03, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.